Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;59(5):675-678.
doi: 10.1016/j.resinv.2021.06.007. Epub 2021 Jun 30.

COVID-19 and acute exacerbation of interstitial lung disease

Yasuhiro Kondoh  1 , Kensuke Kataoka  2 , Masaru Ando  3 , Yukikazu Awaya  4 , Kazuya Ichikado  5 , Mikio Kataoka  6 , Yuko Komase  7 , Masamichi Mineshita  8 , Yasushi Ohno  9 , Hiroaki Okamoto  10 , Takashi Ooki  11 , Yuri Tasaka  12 , Hiromi Tomioka  13 , Takafumi Suda  14
Affiliations

COVID-19 and acute exacerbation of interstitial lung disease

Yasuhiro Kondoh et al. Respir Investig. 2021 Sep.

Abstract

We conducted a study to examine the effect of COVID-19 on the acute exacerbation of interstitial lung disease (AE-ILD) early in the COVID-19 epidemic (January 1-April 30, 2020). An online questionnaire survey was conducted, which was completed by 134 hospitals. During this period, 854 patients with AE-ILD (including 12 cases of COVID-AE-idiopathic pulmonary fibrosis were hospitalized at 128 hospitals. In comparison, the total number of AE-ILD hospitalizations during the same period in 2019 was 894. The number of hospitalizations increased at 17 hospitals, decreased at 27, and remained the same at 88 hospitals in 2020 compared to the same period in 2019. In 2020, COVID-19-related acute exacerbations had a significantly worse prognosis than non-COVID-19-related acute exacerbations in both 30-day and 90-day mortality. Because the prognosis of AE-ILD associated with COVID-19 is extremely poor, prevention of COVID-19 is especially important for patients with ILD.

Keywords: Acute exacerbation; COVID-19; Idiopathic pulmonary fibrosis; Interstitial lung disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors have no conflicts of interest to declare for this article.

References

    1. Rodriguez-Morales A.J., Cardona-Ospina J.A., Gutiérrez-Ocampo E., Villamizar-Peña R., Holguin-Rivera Y., Escalera-Antezana J.P. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Trav Med Infect Dis. 2020;34:101623. https://www.lancovid.org Electronic address: - PMC - PubMed
    1. Collard H.R., Ryerson C.J., Corte T.J., Jenkins G., Kondoh Y., Lederer D.J. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265–275. - PubMed
    1. Wootton S.C., Kim D.S., Kondoh Y., Chen E., Lee J.S., Song J.W. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(12):1698–1702. - PMC - PubMed
    1. Suzuki A., Kondoh Y., Brown K.K., Johkoh T., Kataoka K., Fukuoka J. Acute exacerbations of fibrotic interstitial lung diseases. Respirology. 2020;25(5):525–534. - PubMed
    1. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. RECOVERY Collaborative group. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. - DOI - PMC - PubMed